Navigation Links
Endo Pharmaceuticals Appoints William Montague to Board of Directors
Date:2/26/2009

n where the use of an opioid is appropriate; OPANA(R) ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; and VOLTAREN(R) gel, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment. The company markets its branded pharmaceutical products to physicians in pain management, neurology, surgery, oncology, and primary care. More information, including this and past press releases of Endo Pharmaceuticals, is available at www.endo.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "intend," "guidance" or similar expressions are forward-looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in this press release. Risks and uncertainties include the satisfaction of closing conditions for the acquisition, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act; the tender of a majority of the outstanding shares of common stock of Indevus; the possibility that the transaction will not be completed, or if completed, not completed on a timely basis; the possibility that the acquisition of Indevus is not complementary to Endo; the potential that market segment growth will not follow historical patterns; general industry conditi
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 2015 Dr. Jonathan Glashow a board ... has been named by Castle Connolly as ... Dr. Glashow has been selected by Castle Connolly Medical ... top specialty care doctors in the tri-state metropolitan New ... program, which carefully screens and selects doctors through a ...
(Date:3/5/2015)... 2015 As a result of ... of Clearstream, LLC ’s products, services and ... line of products—led by their mPulse Hand Sanitizer—fits ... Program. , The AAPA—which represents a profession comprising ... and surgical specialties in the U.S.—advocates and educates ...
(Date:3/5/2015)... Today, Earth Source Organics (ESO) ... pollution-free electricity through a partnership with national Clean ... Arcadia Power Clean Energy Partner, ESO now meets ... requirements, joining national brands such as Whole Foods, ... Earth Source Organics joins a growing community of ...
(Date:3/5/2015)... 05, 2015 The Journal of ... a special issue devoted entirely to ... PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococci) ... reaction triggered by infections such as strep throat, ... inflammation of the child's brain. This inflammation causes ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Think it’s tough ... even tougher to get them to brush their teeth. That’s ... parents released today by Delta Dental(1) in conjunction with National ... (45 percent) say getting kids to brush their teeth is ... to do. That’s slightly higher than getting children to eat ...
Breaking Medicine News(10 mins):Health News:Dr. Jonathan Glashow, NYC Orthopedic Surgeon, Named Top Doctor: New York Metro Area 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 3Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 4Health News:Earth Source Organics to Run on Clean Energy from Arcadia Power 2Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 2Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 3Health News:Delta Dental Survey Says Parents Have Harder Time Getting Kids to Brush than to Eat Vegetables 2Health News:Delta Dental Survey Says Parents Have Harder Time Getting Kids to Brush than to Eat Vegetables 3
... Calif., March 20 A former astronaut and veteran ... director of business development for Wyle,s Integrated Science and ... joins Wyle to assist in the company,s continued growth ... and performance services to the Federal Government. He will ...
... the advancement of imaging techniques, the accuracy of preoperative ... of physical function in rectal cancer patients has become ... research article to be published on March 14, 2009 ... the prognostic factors for 5-year survival after local excision ...
... in patients with atrial fibrillation. In the current edition ... 2009; 106(10): 164-70), Thomas Bitter and his coauthors from ... breathing occurs in this form of cardiac arrythmia and ... used cardiorespiratory polygraphy to investigate whether 150 patients (110 ...
... Boehringer Ingelheim today announced that the last ... Randomized Evaluation of Long term Anticoagulant therapy (RE-LY(R)) ... safety of the oral direct thrombin inhibitor dabigatran ... international normalized ratio, INR, 2-3) for the prevention ...
... Even finding it early may not save lives, researchers say, ... that combines ultrasound and a blood test to detect CA125, ... in its early stages and often results in unnecessary surgery, ... recent study that found that these same two tests did ...
... in European UnionCorporate Highlights:- CHMP issued positive ... for treatment of peripheral neuropathic pain in ... with other medicinal products for pain- Qutenza ... for PHNUpcoming 2009 Milestones:- European commercial partnership ...
Cached Medicine News:Health News:Veteran Astronaut Joins Wyle Business Development Staff in Houston 2Health News:Final Patient Completes Treatment In Boehringer Ingelheim's RE-LY(R) Study, The Largest Atrial Fibrillation Outcomes Trial To Date 2Health News:Final Patient Completes Treatment In Boehringer Ingelheim's RE-LY(R) Study, The Largest Atrial Fibrillation Outcomes Trial To Date 3Health News:Final Patient Completes Treatment In Boehringer Ingelheim's RE-LY(R) Study, The Largest Atrial Fibrillation Outcomes Trial To Date 4Health News:Combo Screening Doesn't Spot Early Ovarian Cancer 2Health News:Combo Screening Doesn't Spot Early Ovarian Cancer 3Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 2Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 3Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 4Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 5Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 6Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 7Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 8Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 9Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 10Health News:NeurogesX Reports Fourth Quarter and Year-End 2008 Results 11
(Date:3/5/2015)... 2015  BioPhotas, Inc., an FDA registered medical device ... technologies to treat skin, muscle and joint conditions, today ... Fund to provide BioPhotas, flagship product, the Celluma, ... solutions.  Commenting on the alliance, ... the Celluma at the Warrior Hope and Care Center ...
(Date:3/5/2015)... HAMILTON, N.J. , March 5, 2015 /PRNewswire/ ... laboratory which specializes in high complexity, state-of-the-art, automated ... offering new Human Papillomavirus (HPV) testing which utilizes ... platforms. Each year, approximately 12,000 women ... the United States . Genital Human Papillomaviruses ...
(Date:3/5/2015)... 2015  ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ... acquired the approved abbreviated new drug application ("ANDA") ... 150mg, previously marketed by Teva Pharmaceuticals.  According to ... was approximately $39 million in 2014.   ... CEO of ANI Pharmaceuticals, stated, "This acquisition further ...
Breaking Medicine Technology:BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 2BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 3Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 2Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 3ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 2ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 3
... 2011 /PRNewswire/ -- MEDX, Inc., a ... the next generation T-Quest™ compact gamma camera.  The ... features expanded imaging capabilities to perform parathyroid, sentinel ... other small organ studies.  The Company also announced ...
... 6, 2011 Life Extension, a global authority on ... supplements, has launched a product featuring ChromaDex,s (CDXC.OB) pTeroPure ... food stores and natural retailers. Life Extension ... naturally found in blueberries.  Pterostilbene has been shown ...
Cached Medicine Technology:MEDX Installs Two Next Generation T-Quest™ Compact Gamma Cameras 2MEDX Installs Two Next Generation T-Quest™ Compact Gamma Cameras 3Life Extension® Launches New Product Containing ChromaDex's pTeroPure® Pterostilbene 2Life Extension® Launches New Product Containing ChromaDex's pTeroPure® Pterostilbene 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: